D-mannose is generally well tolerated, but certain groups should avoid it or use it with caution. People with diabetes, those who are pregnant or breastfeeding, individuals with certain rare metabolic disorders, and young children without medical guidance all fall into categories where D-mannose may pose risks that outweigh its potential benefits.
People With Diabetes or Blood Sugar Concerns
D-mannose is a simple sugar, structurally similar to glucose. That alone raises a reasonable flag for anyone managing diabetes or insulin resistance. The picture from animal research is actually more nuanced than you might expect. In mouse models of type 2 diabetes, D-mannose supplementation reduced fasting blood glucose levels, improved long-term blood sugar markers, and increased insulin sensitivity. It did not, however, significantly change random (non-fasting) blood glucose levels.
So why the caution? Those results come from animal studies, not human trials. The way D-mannose interacts with blood sugar regulation in humans, especially in people already taking diabetes medications, remains poorly studied. If you’re on insulin or drugs that lower blood sugar, adding another compound that influences glucose metabolism and insulin sensitivity could create unpredictable effects. The risk isn’t necessarily that D-mannose will spike your blood sugar (most of it is excreted through urine rather than metabolized for energy), but that it could interact with your existing treatment in ways no one has adequately tested. If you have diabetes and want to try D-mannose, monitoring your blood sugar closely and coordinating with your care team is essential.
Pregnant or Breastfeeding Women
There is no established safety profile for D-mannose during pregnancy or breastfeeding. This is a significant gap, especially because urinary tract infections are common during pregnancy and D-mannose is often marketed as a natural prevention strategy. A Cochrane review evaluating D-mannose for UTI prevention specifically flagged pregnancy-related outcomes like preterm birth, stillbirth, and low birthweight as adverse events worth tracking, but the studies reviewed did not include enough pregnant participants to draw any conclusions.
The absence of safety data is the problem here. It doesn’t mean D-mannose is harmful during pregnancy. It means no one has done the work to confirm it’s safe. For a supplement that hasn’t been rigorously tested in this population, the default recommendation is to avoid it unless a healthcare provider specifically recommends it.
People With Digestive Sensitivities
D-mannose can cause bloating, watery diarrhea, and general gastrointestinal discomfort, particularly at higher doses. In one study, half of participants experienced GI disturbances like watery diarrhea and bloating within one to two hours of taking doses above 0.2 grams per kilogram of body weight. For a 150-pound person, that translates to roughly 14 grams. When the dose dropped to 0.15 grams per kilogram, only about 10% of participants had digestive issues. Some participants also reported dizziness at the higher doses.
At the more commonly recommended dose of 2 grams per day (a typical prevention dose used in clinical studies), diarrhea occurred in about 8% of participants. That’s a relatively low rate, but if you already deal with irritable bowel syndrome, chronic diarrhea, or other GI conditions, even a modest increase in loose stools can be disruptive. People with fructose malabsorption or other sugar absorption disorders may be especially sensitive, since D-mannose is a sugar that the body largely doesn’t absorb for energy, meaning much of it passes through the gut where it can draw water into the intestines and feed gut bacteria.
Children Without Medical Supervision
D-mannose supplements are widely available over the counter and not regulated for pediatric dosing. While a Cochrane review included children in its scope when evaluating D-mannose for UTI prevention, it found little to no evidence supporting its use in any population, adults or children. The review identified only seven studies with 719 total participants, mostly adult women with recurrent UTIs. The data could not even be combined meaningfully because the studies used different formulations, populations, and comparison groups.
Children metabolize sugars differently than adults, and their smaller body weight means they reach the dose thresholds associated with side effects much faster. A dose that causes bloating and diarrhea in an adult could cause more significant fluid loss in a child. Without pediatric-specific dosing studies, giving D-mannose to children is essentially guessing.
People With Rare Sugar Metabolism Disorders
Individuals with carbohydrate-deficient glycoprotein syndrome (a group of rare inherited metabolic disorders) have an unusual relationship with mannose. Early research on D-mannose actually explored it as a potential therapy for one form of this condition. But in participants without the syndrome who were given D-mannose during that same research, gastrointestinal side effects were common and dose-dependent. For people with any inherited disorder of sugar metabolism, D-mannose could interfere with already-disrupted metabolic pathways in unpredictable ways.
What the Evidence Actually Shows
Part of the challenge with D-mannose is that the evidence base is thin across the board. The most comprehensive review to date, published through the Cochrane Library, concluded there is “little to no evidence to support or refute the use of D-mannose to prevent or treat UTIs in all populations.” Reported side effects in clinical studies were few and not serious, mostly limited to diarrhea and vaginal burning. But the studies were small, short, and used different formulations, making it hard to draw firm safety conclusions for anyone, let alone vulnerable groups.
D-mannose is sold as a dietary supplement, which means it does not go through the same approval process as pharmaceutical drugs. There are no standardized doses, no required safety testing in special populations, and no mandatory reporting of adverse effects. If you fall into any of the groups above, the lack of evidence isn’t reassuring. It’s a reason to be cautious.